Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupThoracic TumorsDiseaseBile Duct CarcinomaBreast CancerLung Carcinoma, Non-Small CellPancreatic CancerTumor Biomarker DefinedSubgroupNRG1-FusionICD10C24.-C24.0C24.1C24.8C24.9C25.-C34.-C50.-MeSHBile Duct NeoplasmsBiliary TractBiliary Tract NeoplasmsBreast NeoplasmsCarcinoma, Non-Small-Cell LungCommon Bile Duct NeoplasmsNeoplasmsPancreatic NeoplasmsSequenceAntineoplastic therapySubstanceZenocutuzumab SubstanceZenocutuzumab SubstanceZenocutuzumab SubstanceZenocutuzumab Anzahl Substanzen1 RadiotherapySupportive therapySubstanceBalanced Crystalloid SolutionDexamethasoneDimetindenParacetamolSubstanceBalanced Crystalloid SolutionDexamethasoneDimetindenParacetamolSubstanceBalanced Crystalloid SolutionDexamethasoneDimetindenParacetamolSubstanceBalanced Crystalloid SolutionDexamethasoneDimetindenParacetamolAnzahl Substanzen4Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationSecond lineTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlCardiotoxicityDiarrheaEmetogenicityIncrease AminotransferasesInfusion ReactionNauseaVomiting only studiesPublicationAuthorSchram AMDiseaseTumore unterschiedlicher Lokalisation, lokal fortgeschritten oder metastasiert, NRG1-Fusion, Zweitlinie, ECOG 0-2OriginMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA, eNRGy trialProtocols in Revision 1 protocol foundZenocutuzumab 750, Tumor Biomarker Defined (PID3015 V1.0)
